News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,801 Results
Type
Article (14259)
Company Profile (105)
Press Release (259429)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88268)
Career Advice (465)
Deals (15391)
Drug Delivery (73)
Drug Development (36714)
Employer Resources (50)
FDA (6382)
Job Trends (6232)
News (150696)
Policy (14129)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (443)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (23317)
ALS (56)
Alzheimer's disease (478)
Antibody-drug conjugate (ADC) (99)
Approvals (6573)
Artificial intelligence (201)
Autoimmune disease (39)
Automation (12)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (171)
Cancer (1317)
Cardiovascular disease (151)
Career advice (418)
Career pathing (13)
CAR-T (49)
CDC (6)
Cell therapy (150)
Cervical cancer (9)
Clinical research (32018)
Collaboration (725)
Compensation (325)
Complete response letters (33)
COVID-19 (778)
CRISPR (43)
C-suite (432)
Cystic fibrosis (58)
Data (1821)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1382)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (80)
Earnings (33459)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (38977)
Executive appointments (528)
FDA (7480)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (428)
Gene editing (70)
Generative AI (18)
Gene therapy (165)
GLP-1 (439)
Government (1404)
Grass and pollen (4)
Guidances (164)
Healthcare (3575)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (53)
Infectious disease (842)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (60)
IPO (5913)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3448)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (412)
MASH (67)
Medical device (1302)
Medtech (1309)
Mergers & acquisitions (9898)
Metabolic disorders (434)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (37)
Neuroscience (887)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (600)
Now hiring (17)
Obesity (227)
Opinion (141)
Ovarian cancer (39)
Pain (109)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29741)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8305)
Phase 2 (13518)
Phase 3 (12211)
Pipeline (1904)
Policy (135)
Postmarket research (1401)
Preclinical (3338)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (350)
Real estate (2659)
Recruiting (18)
Regulatory (10955)
Reports (15)
Research institute (574)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (48)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1644)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (32)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Last 7 days (176)
Last 30 days (657)
Last 365 days (10404)
2026 (951)
2025 (10712)
2024 (12498)
2023 (14246)
2022 (19557)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20889)
Australia (2687)
California (3177)
Canada (1481)
China (550)
Colorado (143)
Connecticut (129)
Delaware (123)
Europe (40869)
Florida (601)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (348)
India (44)
Indiana (240)
Iowa (2)
Japan (246)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (421)
Massachusetts (2586)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1396)
New Mexico (7)
New York (906)
North Carolina (619)
North Dakota (2)
Northern California (1447)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (715)
Puerto Rico (12)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1387)
Tennessee (53)
Texas (454)
United States (12668)
Utah (59)
Virginia (160)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
273,801 Results for "sebela pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sebela Pharmaceuticals® Announces Submission of New Drug Application to FDA for Tegoprazan for the Treatment of Gastroesophageal Reflux Disease
January 12, 2026
·
10 min read
Press Releases
Sebela Pharmaceuticals® Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 24-Week Maintenance Phase Results
August 8, 2025
·
9 min read
Press Releases
Sebela Pharmaceuticals® Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD
April 23, 2025
·
9 min read
Business
Sebela Pharmaceuticals Announces New Division Named Sebela Women’s Health
Sebela Pharmaceuticals® announced a new division of the company named Sebela Women’s Health along with the appointment of Kelly Culwell, MD, as Head of Research and Development for the division.
November 15, 2022
·
5 min read
Press Releases
FDA Approves MIUDELLA®, the First Hormone-Free Copper Intrauterine System (IUS) in the U.S. in Over 40 Years, from Sebela Women’s Health Inc.
February 26, 2025
·
9 min read
Press Releases
Sebela Women’s Health Announces Publication of Phase 3 Pivotal Study Results for the Investigational Copper 175 mm² Intrauterine Device (IUD) in Contraception
January 24, 2025
·
7 min read
Drug Development
Sebela Women’s Health Announces Further Positive Data from the Pivotal Phase 3 Study of the Investigational Copper 175 mm² Intra-Uterine Device (IUD)
Sebela Women’s Health Inc., a part of Sebela Pharmaceuticals, today announced additional positive data from the pivotal Phase 3 open-label study of the investigational Copper 175 mm2 intra-uterine device (IUD).
October 30, 2023
·
11 min read
FDA
FDA Approves Sebela Pharmaceuticals’ SUFLAVE™ A New Colonoscopy Preparation that Tastes Similar to a Sports Drink
Sebela Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) granted approval of SUFLAVE™ (polyethylene glycol, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution), for colonoscopy preparation in adults.
June 22, 2023
·
9 min read
Business
Sebela Pharmaceuticals® Appoints Victor Parker as Chief Commercial Officer
Sebela Pharmaceuticals, a US pharmaceutical company with a market leading position in gastroenterology and a focus on innovation in women’s health, today announced the appointment of Victor Parker to the position of Chief Commercial Officer.
October 24, 2022
·
3 min read
Business
Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada
Sebela Pharmaceuticals® has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the United States and Canada.
October 19, 2022
·
4 min read
1 of 27,381
Next
